Information  X 
Enter a valid email address

Motif Bio widens H1 pretax loss

By BFN News | 07:44 AM | Tuesday 16 August, 2016

Motif Bio widens H1 pretax loss of $14.2m, from a loss of $1.9m. It is pleased that lead product iclaprim is in its final stage of development. This followed the the dosing of the first patient with iclaprim in March this year in Motif's two REVIVE Phase 3 clinical trials in ABSSSI, said CEO Graham Lumsden. "This is a significant milestone for the company and we expect the data read-out from these two trials in the second half of 2017. We are encouraged to see that patient enrollment to date is ahead of our projections," he added. "We believe that iclaprim, a novel antibiotic with an under-utilized mechanism of action, if approved, could offer advantages compared to the current standard of care for high-risk, seriously ill patients hospitalised with ABSSSI and who also have renal impairment or diabetes." Story provided by

a d v e r t i s e m e n t